+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Allergy Immunotherapy Market By Type: Global Opportunity Analysis and Industry Forecast, 2024-2033

  • PDF Icon

    Report

  • 216 Pages
  • July 2024
  • Region: Global
  • Allied Market Research
  • ID: 5993978
Description Jump to:
The allergy immunotherapy market was valued at $1.8 billion in 2023, and is projected to reach $4.9 billion by 2033, growing at a CAGR of 10.4% from 2024 to 2033.

Allergy immunotherapy is a preventative treatment for allergies that aims to mitigate the severity of allergic reactions to specific allergens such as house dust mites, bee venom, and grass pollens. This therapy involves gradual increase in administration of doses of the allergen to which an individual is allergic, thus making the immune systems less sensitive to the allergen and reducing the symptoms of allergy. The therapy can lead to long-term relief and decreased dependence on allergy medications.

The growth of the global allergy immunotherapy market is majorly driven by alarming rise in the prevalence of allergic conditions such as allergic rhinitis, asthma, and food allergies coupled with increase in awareness about allergy immunotherapy among patients and healthcare providers. Based on a 2011 study published in the White Book on Allergy, the prevalence rate of allergic rhinitis from 1% to 18%, skin allergies from 2% to 10%, and asthma ranges from 1% to 20% in various populations. Moreover, increase in preference of patients for effective and long-term solutions to allergy management fosters the demand for allergy immunotherapy, which significantly contributes toward the growth of the market. Furthermore, increase in trend toward personalized medicine is driving the demand for tailored immunotherapy treatments that address individual patient needs and specific allergies, which fosters the market growth. However, high cost of the associated with allergy immunotherapy and increase in concerns about the side effects of the treatment act as the key deterrent factors of the market. On the contrary, increase in healthcare expenditure in emerging markets is facilitating the access to advanced treatments like allergy immunotherapy, which is expected to offer remunerative opportunities for the growth of the market during the forecast period. Moreover, advancements in immunotherapy techniques, such as the development of sublingual immunotherapy and improved formulations of subcutaneous immunotherapy, are making treatments more effective and accessible, which are expected to open new avenues for the market growth.

The global allergy immunotherapy market is segmented into type, application, distribution channel, and region. On the basis of type, the market is categorized into subcutaneous immunotherapy and sublingual immunotherapy. By application, it is segregated into allergy rhinitis, asthma, food allergy, and others. Depending on distribution channel, it is fragmented into hospital pharmacies, retail, and online pharmacies. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

On the basis of type, the subcutaneous immunotherapy (SCIT) segment held the highest market share in 2023.

By application, the allergic rhinitis segment is expected to exhibit highest growth rate by 2033.

Depending on distribution channel,, the hospital pharmacies segment is anticipated to gain high prominence during the forecast period.

Region wise, North America is projected to dominate the allergy immunotherapy market in the coming years.

Competition Analysis

Competitive analysis and profiles of the major players in the global allergy immunotherapy market include Torii Pharmaceutical Co., Ltd., Biomay AG, ALK-Abello A/S, Allergy Therapeutics, Allovate, LLC, HAL Allergy Group, Jubliant Pharma, Leti Pharma, Merck KGaA, and Stallergenes Greer. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to sustain the intense competition and garner a strong foothold in the global market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Expanded list for Company Profiles
  • Reimbursement Scenario

Key Market Segments

By Type

  • Subcutaneous Immunotherapy
  • Sublingual Immunotherapy

By Application

  • Allergy Rhinitis
  • Asthma
  • Food Allergy
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail
  • Online Pharmacies

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • France
  • Germany
  • Italy
  • Spain
  • UK
  • Rest of Europe
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • South Africa
  • Saudi Arabia
  • Rest of LAMEA

Key Market Players

  • Torii Pharmaceutical Co., Ltd.
  • Biomay AG
  • ALK-Abello A/S
  • Allergy Therapeutics
  • Allovate, LLC
  • HAL Allergy Group
  • Jubliant Pharma
  • Leti Pharma
  • Merck KGaA
  • Stallergenes Greer

 

Please note:

  • Online Access price format is valid for 60 days access. Printing is not enabled.
  • PDF Single and Enterprise price formats enable printing.

 

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Threat of New Entrants
3.3.3. Threat of Substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining Power among Buyers
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
CHAPTER 4: ALLERGY IMMUNOTHERAPY MARKET, BY TYPE
4.1. Market Overview
4.1.1 Market Size and Forecast, By Type
4.2. Subcutaneous Immunotherapy
4.2.1. Key Market Trends, Growth Factors and Opportunities
4.2.2. Market Size and Forecast, By Region
4.2.3. Market Share Analysis, By Country
4.3. Sublingual Immunotherapy
4.3.1. Key Market Trends, Growth Factors and Opportunities
4.3.2. Market Size and Forecast, By Region
4.3.3. Market Share Analysis, By Country
CHAPTER 5: ALLERGY IMMUNOTHERAPY MARKET, BY APPLICATION
5.1. Market Overview
5.1.1 Market Size and Forecast, By Application
5.2. Allergy Rhinitis
5.2.1. Key Market Trends, Growth Factors and Opportunities
5.2.2. Market Size and Forecast, By Region
5.2.3. Market Share Analysis, By Country
5.3. Asthma
5.3.1. Key Market Trends, Growth Factors and Opportunities
5.3.2. Market Size and Forecast, By Region
5.3.3. Market Share Analysis, By Country
5.4. Food Allergy
5.4.1. Key Market Trends, Growth Factors and Opportunities
5.4.2. Market Size and Forecast, By Region
5.4.3. Market Share Analysis, By Country
5.5. Others
5.5.1. Key Market Trends, Growth Factors and Opportunities
5.5.2. Market Size and Forecast, By Region
5.5.3. Market Share Analysis, By Country
CHAPTER 6: ALLERGY IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL
6.1. Market Overview
6.1.1 Market Size and Forecast, By Distribution Channel
6.2. Hospital Pharmacies
6.2.1. Key Market Trends, Growth Factors and Opportunities
6.2.2. Market Size and Forecast, By Region
6.2.3. Market Share Analysis, By Country
6.3. Retail
6.3.1. Key Market Trends, Growth Factors and Opportunities
6.3.2. Market Size and Forecast, By Region
6.3.3. Market Share Analysis, By Country
6.4. Online Pharmacies
6.4.1. Key Market Trends, Growth Factors and Opportunities
6.4.2. Market Size and Forecast, By Region
6.4.3. Market Share Analysis, By Country
CHAPTER 7: ALLERGY IMMUNOTHERAPY MARKET, BY REGION
7.1. Market Overview
7.1.1 Market Size and Forecast, By Region
7.2. North America
7.2.1. Key Market Trends and Opportunities
7.2.2. Market Size and Forecast, By Type
7.2.3. Market Size and Forecast, By Application
7.2.4. Market Size and Forecast, By Distribution Channel
7.2.5. Market Size and Forecast, By Country
7.2.6. U.S. Allergy Immunotherapy Market
7.2.6.1. Market Size and Forecast, By Type
7.2.6.2. Market Size and Forecast, By Application
7.2.6.3. Market Size and Forecast, By Distribution Channel
7.2.7. Canada Allergy Immunotherapy Market
7.2.7.1. Market Size and Forecast, By Type
7.2.7.2. Market Size and Forecast, By Application
7.2.7.3. Market Size and Forecast, By Distribution Channel
7.2.8. Mexico Allergy Immunotherapy Market
7.2.8.1. Market Size and Forecast, By Type
7.2.8.2. Market Size and Forecast, By Application
7.2.8.3. Market Size and Forecast, By Distribution Channel
7.3. Europe
7.3.1. Key Market Trends and Opportunities
7.3.2. Market Size and Forecast, By Type
7.3.3. Market Size and Forecast, By Application
7.3.4. Market Size and Forecast, By Distribution Channel
7.3.5. Market Size and Forecast, By Country
7.3.6. France Allergy Immunotherapy Market
7.3.6.1. Market Size and Forecast, By Type
7.3.6.2. Market Size and Forecast, By Application
7.3.6.3. Market Size and Forecast, By Distribution Channel
7.3.7. Germany Allergy Immunotherapy Market
7.3.7.1. Market Size and Forecast, By Type
7.3.7.2. Market Size and Forecast, By Application
7.3.7.3. Market Size and Forecast, By Distribution Channel
7.3.8. Italy Allergy Immunotherapy Market
7.3.8.1. Market Size and Forecast, By Type
7.3.8.2. Market Size and Forecast, By Application
7.3.8.3. Market Size and Forecast, By Distribution Channel
7.3.9. Spain Allergy Immunotherapy Market
7.3.9.1. Market Size and Forecast, By Type
7.3.9.2. Market Size and Forecast, By Application
7.3.9.3. Market Size and Forecast, By Distribution Channel
7.3.10. UK Allergy Immunotherapy Market
7.3.10.1. Market Size and Forecast, By Type
7.3.10.2. Market Size and Forecast, By Application
7.3.10.3. Market Size and Forecast, By Distribution Channel
7.3.11. Rest Of Europe Allergy Immunotherapy Market
7.3.11.1. Market Size and Forecast, By Type
7.3.11.2. Market Size and Forecast, By Application
7.3.11.3. Market Size and Forecast, By Distribution Channel
7.4. Asia-Pacific
7.4.1. Key Market Trends and Opportunities
7.4.2. Market Size and Forecast, By Type
7.4.3. Market Size and Forecast, By Application
7.4.4. Market Size and Forecast, By Distribution Channel
7.4.5. Market Size and Forecast, By Country
7.4.6. China Allergy Immunotherapy Market
7.4.6.1. Market Size and Forecast, By Type
7.4.6.2. Market Size and Forecast, By Application
7.4.6.3. Market Size and Forecast, By Distribution Channel
7.4.7. Japan Allergy Immunotherapy Market
7.4.7.1. Market Size and Forecast, By Type
7.4.7.2. Market Size and Forecast, By Application
7.4.7.3. Market Size and Forecast, By Distribution Channel
7.4.8. India Allergy Immunotherapy Market
7.4.8.1. Market Size and Forecast, By Type
7.4.8.2. Market Size and Forecast, By Application
7.4.8.3. Market Size and Forecast, By Distribution Channel
7.4.9. South Korea Allergy Immunotherapy Market
7.4.9.1. Market Size and Forecast, By Type
7.4.9.2. Market Size and Forecast, By Application
7.4.9.3. Market Size and Forecast, By Distribution Channel
7.4.10. Australia Allergy Immunotherapy Market
7.4.10.1. Market Size and Forecast, By Type
7.4.10.2. Market Size and Forecast, By Application
7.4.10.3. Market Size and Forecast, By Distribution Channel
7.4.11. Rest of Asia-Pacific Allergy Immunotherapy Market
7.4.11.1. Market Size and Forecast, By Type
7.4.11.2. Market Size and Forecast, By Application
7.4.11.3. Market Size and Forecast, By Distribution Channel
7.5. LAMEA
7.5.1. Key Market Trends and Opportunities
7.5.2. Market Size and Forecast, By Type
7.5.3. Market Size and Forecast, By Application
7.5.4. Market Size and Forecast, By Distribution Channel
7.5.5. Market Size and Forecast, By Country
7.5.6. Brazil Allergy Immunotherapy Market
7.5.6.1. Market Size and Forecast, By Type
7.5.6.2. Market Size and Forecast, By Application
7.5.6.3. Market Size and Forecast, By Distribution Channel
7.5.7. South Africa Allergy Immunotherapy Market
7.5.7.1. Market Size and Forecast, By Type
7.5.7.2. Market Size and Forecast, By Application
7.5.7.3. Market Size and Forecast, By Distribution Channel
7.5.8. Saudi Arabia Allergy Immunotherapy Market
7.5.8.1. Market Size and Forecast, By Type
7.5.8.2. Market Size and Forecast, By Application
7.5.8.3. Market Size and Forecast, By Distribution Channel
7.5.9. Rest of LAMEA Allergy Immunotherapy Market
7.5.9.1. Market Size and Forecast, By Type
7.5.9.2. Market Size and Forecast, By Application
7.5.9.3. Market Size and Forecast, By Distribution Channel
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top Winning Strategies
8.3. Product Mapping Of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top Player Positioning, 2023
CHAPTER 9: COMPANY PROFILES
9.1. Torii Pharmaceutical Co., Ltd.
9.1.1. Company Overview
9.1.2. Key Executives
9.1.3. Company Snapshot
9.1.4. Operating Business Segments
9.1.5. Product Portfolio
9.1.6. Business Performance
9.1.7. Key Strategic Moves and Developments
9.2. Biomay AG
9.2.1. Company Overview
9.2.2. Key Executives
9.2.3. Company Snapshot
9.2.4. Operating Business Segments
9.2.5. Product Portfolio
9.2.6. Business Performance
9.2.7. Key Strategic Moves and Developments
9.3. ALK-Abello A/S
9.3.1. Company Overview
9.3.2. Key Executives
9.3.3. Company Snapshot
9.3.4. Operating Business Segments
9.3.5. Product Portfolio
9.3.6. Business Performance
9.3.7. Key Strategic Moves and Developments
9.4. Allergy Therapeutics
9.4.1. Company Overview
9.4.2. Key Executives
9.4.3. Company Snapshot
9.4.4. Operating Business Segments
9.4.5. Product Portfolio
9.4.6. Business Performance
9.4.7. Key Strategic Moves and Developments
9.5. Allovate, LLC
9.5.1. Company Overview
9.5.2. Key Executives
9.5.3. Company Snapshot
9.5.4. Operating Business Segments
9.5.5. Product Portfolio
9.5.6. Business Performance
9.5.7. Key Strategic Moves and Developments
9.6. HAL Allergy Group
9.6.1. Company Overview
9.6.2. Key Executives
9.6.3. Company Snapshot
9.6.4. Operating Business Segments
9.6.5. Product Portfolio
9.6.6. Business Performance
9.6.7. Key Strategic Moves and Developments
9.7. Jubliant Pharma
9.7.1. Company Overview
9.7.2. Key Executives
9.7.3. Company Snapshot
9.7.4. Operating Business Segments
9.7.5. Product Portfolio
9.7.6. Business Performance
9.7.7. Key Strategic Moves and Developments
9.8. Leti Pharma
9.8.1. Company Overview
9.8.2. Key Executives
9.8.3. Company Snapshot
9.8.4. Operating Business Segments
9.8.5. Product Portfolio
9.8.6. Business Performance
9.8.7. Key Strategic Moves and Developments
9.9. Merck KGaA
9.9.1. Company Overview
9.9.2. Key Executives
9.9.3. Company Snapshot
9.9.4. Operating Business Segments
9.9.5. Product Portfolio
9.9.6. Business Performance
9.9.7. Key Strategic Moves and Developments
9.10. Stallergenes Greer
9.10.1. Company Overview
9.10.2. Key Executives
9.10.3. Company Snapshot
9.10.4. Operating Business Segments
9.10.5. Product Portfolio
9.10.6. Business Performance
9.10.7. Key Strategic Moves and Developments
LIST OF TABLES
TABLE 1. GLOBAL ALLERGY IMMUNOTHERAPY MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 2. ALLERGY IMMUNOTHERAPY MARKET FOR SUBCUTANEOUS IMMUNOTHERAPY, BY REGION, 2024 - 2033 ($BILLION)
TABLE 3. ALLERGY IMMUNOTHERAPY MARKET FOR SUBLINGUAL IMMUNOTHERAPY, BY REGION, 2024 - 2033 ($BILLION)
TABLE 4. GLOBAL ALLERGY IMMUNOTHERAPY MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 5. ALLERGY IMMUNOTHERAPY MARKET FOR ALLERGY RHINITIS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 6. ALLERGY IMMUNOTHERAPY MARKET FOR ASTHMA, BY REGION, 2024 - 2033 ($BILLION)
TABLE 7. ALLERGY IMMUNOTHERAPY MARKET FOR FOOD ALLERGY, BY REGION, 2024 - 2033 ($BILLION)
TABLE 8. ALLERGY IMMUNOTHERAPY MARKET FOR OTHERS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 9. GLOBAL ALLERGY IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 10. ALLERGY IMMUNOTHERAPY MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2024 - 2033 ($BILLION)
TABLE 11. ALLERGY IMMUNOTHERAPY MARKET FOR RETAIL, BY REGION, 2024 - 2033 ($BILLION)
TABLE 12. ALLERGY IMMUNOTHERAPY MARKET FOR ONLINE PHARMACIES, BY REGION, 2024 - 2033 ($BILLION)
TABLE 13. ALLERGY IMMUNOTHERAPY MARKET, BY REGION, 2024 - 2033 ($BILLION)
TABLE 14. NORTH AMERICA ALLERGY IMMUNOTHERAPY MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 15. NORTH AMERICA ALLERGY IMMUNOTHERAPY MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 16. NORTH AMERICA ALLERGY IMMUNOTHERAPY MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 17. NORTH AMERICA ALLERGY IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 18. U.S. ALLERGY IMMUNOTHERAPY MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 19. U.S. ALLERGY IMMUNOTHERAPY MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 20. U.S. ALLERGY IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 21. CANADA ALLERGY IMMUNOTHERAPY MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 22. CANADA ALLERGY IMMUNOTHERAPY MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 23. CANADA ALLERGY IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 24. MEXICO ALLERGY IMMUNOTHERAPY MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 25. MEXICO ALLERGY IMMUNOTHERAPY MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 26. MEXICO ALLERGY IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 27. EUROPE ALLERGY IMMUNOTHERAPY MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 28. EUROPE ALLERGY IMMUNOTHERAPY MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 29. EUROPE ALLERGY IMMUNOTHERAPY MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 30. EUROPE ALLERGY IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 31. FRANCE ALLERGY IMMUNOTHERAPY MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 32. FRANCE ALLERGY IMMUNOTHERAPY MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 33. FRANCE ALLERGY IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 34. GERMANY ALLERGY IMMUNOTHERAPY MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 35. GERMANY ALLERGY IMMUNOTHERAPY MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 36. GERMANY ALLERGY IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 37. ITALY ALLERGY IMMUNOTHERAPY MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 38. ITALY ALLERGY IMMUNOTHERAPY MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 39. ITALY ALLERGY IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 40. SPAIN ALLERGY IMMUNOTHERAPY MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 41. SPAIN ALLERGY IMMUNOTHERAPY MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 42. SPAIN ALLERGY IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 43. UK ALLERGY IMMUNOTHERAPY MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 44. UK ALLERGY IMMUNOTHERAPY MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 45. UK ALLERGY IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 46. REST OF EUROPE ALLERGY IMMUNOTHERAPY MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 47. REST OF EUROPE ALLERGY IMMUNOTHERAPY MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 48. REST OF EUROPE ALLERGY IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 49. ASIA-PACIFIC ALLERGY IMMUNOTHERAPY MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 50. ASIA-PACIFIC ALLERGY IMMUNOTHERAPY MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 51. ASIA-PACIFIC ALLERGY IMMUNOTHERAPY MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 52. ASIA-PACIFIC ALLERGY IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 53. CHINA ALLERGY IMMUNOTHERAPY MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 54. CHINA ALLERGY IMMUNOTHERAPY MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 55. CHINA ALLERGY IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 56. JAPAN ALLERGY IMMUNOTHERAPY MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 57. JAPAN ALLERGY IMMUNOTHERAPY MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 58. JAPAN ALLERGY IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 59. INDIA ALLERGY IMMUNOTHERAPY MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 60. INDIA ALLERGY IMMUNOTHERAPY MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 61. INDIA ALLERGY IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 62. SOUTH KOREA ALLERGY IMMUNOTHERAPY MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 63. SOUTH KOREA ALLERGY IMMUNOTHERAPY MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 64. SOUTH KOREA ALLERGY IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 65. AUSTRALIA ALLERGY IMMUNOTHERAPY MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 66. AUSTRALIA ALLERGY IMMUNOTHERAPY MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 67. AUSTRALIA ALLERGY IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 68. REST OF ASIA-PACIFIC ALLERGY IMMUNOTHERAPY MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 69. REST OF ASIA-PACIFIC ALLERGY IMMUNOTHERAPY MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 70. REST OF ASIA-PACIFIC ALLERGY IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 71. LAMEA ALLERGY IMMUNOTHERAPY MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 72. LAMEA ALLERGY IMMUNOTHERAPY MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 73. LAMEA ALLERGY IMMUNOTHERAPY MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 74. LAMEA ALLERGY IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 75. BRAZIL ALLERGY IMMUNOTHERAPY MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 76. BRAZIL ALLERGY IMMUNOTHERAPY MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 77. BRAZIL ALLERGY IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 78. SOUTH AFRICA ALLERGY IMMUNOTHERAPY MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 79. SOUTH AFRICA ALLERGY IMMUNOTHERAPY MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 80. SOUTH AFRICA ALLERGY IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 81. SAUDI ARABIA ALLERGY IMMUNOTHERAPY MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 82. SAUDI ARABIA ALLERGY IMMUNOTHERAPY MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 83. SAUDI ARABIA ALLERGY IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 84. REST OF LAMEA ALLERGY IMMUNOTHERAPY MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 85. REST OF LAMEA ALLERGY IMMUNOTHERAPY MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 86. REST OF LAMEA ALLERGY IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 87. TORII PHARMACEUTICAL CO., LTD.: KEY EXECUTIVES
TABLE 88. TORII PHARMACEUTICAL CO., LTD.: COMPANY SNAPSHOT
TABLE 89. TORII PHARMACEUTICAL CO., LTD.: OPERATING SEGMENTS
TABLE 90. TORII PHARMACEUTICAL CO., LTD.: PRODUCT PORTFOLIO
TABLE 91. TORII PHARMACEUTICAL CO., LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 92. BIOMAY AG: KEY EXECUTIVES
TABLE 93. BIOMAY AG: COMPANY SNAPSHOT
TABLE 94. BIOMAY AG: OPERATING SEGMENTS
TABLE 95. BIOMAY AG: PRODUCT PORTFOLIO
TABLE 96. BIOMAY AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 97. ALK-ABELLO A/S: KEY EXECUTIVES
TABLE 98. ALK-ABELLO A/S: COMPANY SNAPSHOT
TABLE 99. ALK-ABELLO A/S: OPERATING SEGMENTS
TABLE 100. ALK-ABELLO A/S: PRODUCT PORTFOLIO
TABLE 101. ALK-ABELLO A/S: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 102. ALLERGY THERAPEUTICS: KEY EXECUTIVES
TABLE 103. ALLERGY THERAPEUTICS: COMPANY SNAPSHOT
TABLE 104. ALLERGY THERAPEUTICS: OPERATING SEGMENTS
TABLE 105. ALLERGY THERAPEUTICS: PRODUCT PORTFOLIO
TABLE 106. ALLERGY THERAPEUTICS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 107. ALLOVATE, LLC: KEY EXECUTIVES
TABLE 108. ALLOVATE, LLC: COMPANY SNAPSHOT
TABLE 109. ALLOVATE, LLC: OPERATING SEGMENTS
TABLE 110. ALLOVATE, LLC: PRODUCT PORTFOLIO
TABLE 111. ALLOVATE, LLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 112. HAL ALLERGY GROUP: KEY EXECUTIVES
TABLE 113. HAL ALLERGY GROUP: COMPANY SNAPSHOT
TABLE 114. HAL ALLERGY GROUP: OPERATING SEGMENTS
TABLE 115. HAL ALLERGY GROUP: PRODUCT PORTFOLIO
TABLE 116. HAL ALLERGY GROUP: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 117. JUBLIANT PHARMA: KEY EXECUTIVES
TABLE 118. JUBLIANT PHARMA: COMPANY SNAPSHOT
TABLE 119. JUBLIANT PHARMA: OPERATING SEGMENTS
TABLE 120. JUBLIANT PHARMA: PRODUCT PORTFOLIO
TABLE 121. JUBLIANT PHARMA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 122. LETI PHARMA: KEY EXECUTIVES
TABLE 123. LETI PHARMA: COMPANY SNAPSHOT
TABLE 124. LETI PHARMA: OPERATING SEGMENTS
TABLE 125. LETI PHARMA: PRODUCT PORTFOLIO
TABLE 126. LETI PHARMA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 127. MERCK KGAA: KEY EXECUTIVES
TABLE 128. MERCK KGAA: COMPANY SNAPSHOT
TABLE 129. MERCK KGAA: OPERATING SEGMENTS
TABLE 130. MERCK KGAA: PRODUCT PORTFOLIO
TABLE 131. MERCK KGAA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 132. STALLERGENES GREER: KEY EXECUTIVES
TABLE 133. STALLERGENES GREER: COMPANY SNAPSHOT
TABLE 134. STALLERGENES GREER: OPERATING SEGMENTS
TABLE 135. STALLERGENES GREER: PRODUCT PORTFOLIO
TABLE 136. STALLERGENES GREER: KEY STRATEGIC MOVES AND DEVELOPMENTS
LIST OF FIGURES
FIGURE 1. GLOBAL ALLERGY IMMUNOTHERAPY MARKET, 2024 - 2033
FIGURE 2. SEGMENTATION OF ALLERGY IMMUNOTHERAPY MARKET, 2024 - 2033
FIGURE 3. TOP INVESTMENT POCKET IN ALLERGY IMMUNOTHERAPY MARKET
FIGURE 4. MODERATE BARGAINING POWER OF BUYERS
FIGURE 5. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 6. MODERATE THREAT OF NEW ENTRANTS
FIGURE 7. LOW THREAT OF SUBSTITUTION
FIGURE 8. HIGH COMPETITIVE RIVALRY
FIGURE 9. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALALLERGY IMMUNOTHERAPY MARKET
FIGURE 10. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SEGMENTATION, BY TYPE
FIGURE 11. ALLERGY IMMUNOTHERAPY MARKET FOR SUBCUTANEOUS IMMUNOTHERAPY, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 12. ALLERGY IMMUNOTHERAPY MARKET FOR SUBLINGUAL IMMUNOTHERAPY, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 13. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SEGMENTATION, BY APPLICATION
FIGURE 14. ALLERGY IMMUNOTHERAPY MARKET FOR ALLERGY RHINITIS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 15. ALLERGY IMMUNOTHERAPY MARKET FOR ASTHMA, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 16. ALLERGY IMMUNOTHERAPY MARKET FOR FOOD ALLERGY, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 17. ALLERGY IMMUNOTHERAPY MARKET FOR OTHERS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 18. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SEGMENTATION, BY DISTRIBUTION CHANNEL
FIGURE 19. ALLERGY IMMUNOTHERAPY MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 20. ALLERGY IMMUNOTHERAPY MARKET FOR RETAIL, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 21. ALLERGY IMMUNOTHERAPY MARKET FOR ONLINE PHARMACIES, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 22. TOP WINNING STRATEGIES, BY YEAR, 2021-2023*
FIGURE 23. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2021-2023*
FIGURE 24. TOP WINNING STRATEGIES, BY COMPANY, 2021-2023*
FIGURE 25. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 26. COMPETITIVE DASHBOARD
FIGURE 27. COMPETITIVE HEATMAP: ALLERGY IMMUNOTHERAPY MARKET
FIGURE 28. TOP PLAYER POSITIONING, 2023
FIGURE 29. TORII PHARMACEUTICAL CO., LTD.: NET SALES, 2021-2023 ($BILLION)
FIGURE 30. TORII PHARMACEUTICAL CO., LTD.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 31. TORII PHARMACEUTICAL CO., LTD.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 32. BIOMAY AG: NET SALES, 2021-2023 ($BILLION)
FIGURE 33. BIOMAY AG: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 34. BIOMAY AG: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 35. ALK-ABELLO A/S: NET SALES, 2021-2023 ($BILLION)
FIGURE 36. ALK-ABELLO A/S: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 37. ALK-ABELLO A/S: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 38. ALLERGY THERAPEUTICS: NET SALES, 2021-2023 ($BILLION)
FIGURE 39. ALLERGY THERAPEUTICS: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 40. ALLERGY THERAPEUTICS: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 41. ALLOVATE, LLC: NET SALES, 2021-2023 ($BILLION)
FIGURE 42. ALLOVATE, LLC: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 43. ALLOVATE, LLC: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 44. HAL ALLERGY GROUP: NET SALES, 2021-2023 ($BILLION)
FIGURE 45. HAL ALLERGY GROUP: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 46. HAL ALLERGY GROUP: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 47. JUBLIANT PHARMA: NET SALES, 2021-2023 ($BILLION)
FIGURE 48. JUBLIANT PHARMA: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 49. JUBLIANT PHARMA: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 50. LETI PHARMA: NET SALES, 2021-2023 ($BILLION)
FIGURE 51. LETI PHARMA: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 52. LETI PHARMA: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 53. MERCK KGAA: NET SALES, 2021-2023 ($BILLION)
FIGURE 54. MERCK KGAA: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 55. MERCK KGAA: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 56. STALLERGENES GREER: NET SALES, 2021-2023 ($BILLION)
FIGURE 57. STALLERGENES GREER: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 58. STALLERGENES GREER: REVENUE SHARE, BY REGION, 2023 (%)

Companies Mentioned

  • Torii Pharmaceutical Co., Ltd.
  • Biomay AG
  • ALK-Abello A/S
  • Allergy Therapeutics
  • Allovate, LLC
  • HAL Allergy Group
  • Jubliant Pharma
  • Leti Pharma
  • Merck KGaA
  • Stallergenes Greer

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages216
PublishedJuly 2024
Forecast Period2023 - 2033
Estimated Market Value ( USD ) in 2023 $ 1.8 billion
Forecasted Market Value ( USD ) by 2033 $ 4.9 billion
Compound Annual Growth Rate10.4%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Allergy Immunotherapy Global Market Report 2024 - Product Image

Allergy Immunotherapy Global Market Report 2024

  • Report
  • 200 Pages
  • Global
From
Global Allergy Immunotherapies Market 2024-2028 - Product Image

Global Allergy Immunotherapies Market 2024-2028

  • Report
  • 167 Pages
  • Global
From
Allergy Immunotherapies Market Report by Treatment Type, Allergy Type, Distribution Channel, and Region 2024-2032 - Product Image

Allergy Immunotherapies Market Report by Treatment Type, Allergy Type, Distribution Channel, and Region 2024-2032

  • Report
  • 141 Pages
  • Global
From
Global Allergy Immunotherapy Market by Type (SCIT, SLIT), Allergy Type (Allergic Rhinitis, Asthma, Food Allergy), Distribution Channel - Forecast 2024-2030 - Product Image

Global Allergy Immunotherapy Market by Type (SCIT, SLIT), Allergy Type (Allergic Rhinitis, Asthma, Food Allergy), Distribution Channel - Forecast 2024-2030

  • Report
  • 184 Pages
  • Global
From
Global Allergy Immunotherapy Market Report and Forecast 2024-2032 - Product Image

Global Allergy Immunotherapy Market Report and Forecast 2024-2032

  • Report
  • 200 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.